Clinical Research Progress of L-carnitine in the Treatment of Primary Carnitine Deficiency / 医药导报
Herald of Medicine
; (12): 402-407, 2024.
Article
de Zh
| WPRIM
| ID: wpr-1023727
Bibliothèque responsable:
WPRO
ABSTRACT
L-carnitine is a carrier that assist in transport of long-chain fatty acids into mitochondria and an effective drug for treating primary carnitine deficiency(PCD).Starting supplementation as early as possible before irreversible organ damage oc-cured can alleviate organ damage,reduce the risk of sudden death,and improve the quality of life.However,in recent years,some studies have suggested that long-term oral L-carnitine has potential risks,the metabolism of L-carnitine through intestinal flora re-sults in the production of trimethylamine oxide(TMAO),which can increase the risk of cardiovascular disease(CVD).There-fore,this paper summarizes the clinical research progress of L-carnitine in treating PCD to provide a theoretical basis for the clini-cal application of L-carnitine in PCD.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Herald of Medicine
Année:
2024
Type:
Article